Publicaciones en las que colabora con María Josefa Guerra Seijas (20)

2018

  1. Bidirectional Neural Interaction Between Central Dopaminergic and Gut Lesions in Parkinson’s Disease Models

    Molecular Neurobiology, Vol. 55, Núm. 9, pp. 7297-7316

2017

  1. Brain renin-angiotensin system and microglial polarization: Implications for aging and neurodegeneration

    Frontiers in Aging Neuroscience, Vol. 9, Núm. MAY

  2. Dopamine modulates astroglial and microglial activity via glial renin-angiotensin system in cultures

    Brain, Behavior, and Immunity, Vol. 62, pp. 277-290

2016

  1. Menopause and Parkinson's disease. Interaction between estrogens and brain renin-angiotensin system in dopaminergic degeneration

    Frontiers in Neuroendocrinology, Vol. 43, pp. 44-59

2015

  1. Interaction between NADPH-oxidase and Rho-kinase in angiotensin II-induced microglial activation

    GLIA, Vol. 63, Núm. 3, pp. 466-482

  2. Rho Kinase and Dopaminergic Degeneration: A Promising Therapeutic Target for Parkinsons Disease

    Neuroscientist, Vol. 21, Núm. 6, pp. 616-629

2014

  1. Inhibition of the microglial response is essential for the neuroprotective effects of Rho-kinase inhibitors on MPTP-induced dopaminergic cell death

    Neuropharmacology, Vol. 85, pp. 1-8

  2. Microglial TNF-α mediates enhancement of dopaminergic degeneration by brain angiotensin

    GLIA, Vol. 62, Núm. 1, pp. 145-157

2013

  1. Dopaminergic degeneration is enhanced by chronic brain hypoperfusion and inhibited by angiotensin receptor blockage

    Age, Vol. 35, Núm. 5, pp. 1675-1690

  2. Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson's disease

    Neurobiology of Disease, Vol. 58, pp. 209-219

2012

  1. Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration

    Neurobiology of Aging, Vol. 33, Núm. 1, pp. 204.e1-204.e11

  2. Brain angiotensin and dopaminergic degeneration: Relevance to Parkinson’s disease

    American Journal of Neurodegenerative Diseases, Vol. 1, Núm. 3, pp. 226-244

  3. Dopaminergic neuroprotection of hormonal replacement therapy in young and aged menopausal rats: Role of the brain angiotensin system

    Brain, Vol. 135, Núm. 1, pp. 124-138

  4. Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: Effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease

    Journal of Neuroinflammation, Vol. 9

  5. Involvement of microglial RhoA/Rho-Kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors

    Neurobiology of Disease, Vol. 47, Núm. 2, pp. 268-279

2011

  1. Aging, angiotensin system and dopaminergic degeneration in the substantia nigra

    Aging and Disease, Vol. 2, Núm. 3, pp. 257-274

  2. Renin angiotensin system and gender differences in dopaminergic degeneration

    Molecular Neurodegeneration, Vol. 6, Núm. 1

2010

  1. Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal Parkinson's disease

    Experimental Neurology, Vol. 224, Núm. 2, pp. 517-526

2009

  1. Aging and sedentarism decrease vascularization and VEGF levels in the rat substantia nigra. Implications for Parkinson's disease

    Journal of Cerebral Blood Flow and Metabolism, Vol. 29, Núm. 2, pp. 230-234

  2. The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: Relevance to progression of the disease

    Journal of Neurochemistry, Vol. 109, Núm. 2, pp. 656-669